BIBLIOGRAPHY
1- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet . 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
2- Channappanavar R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–193.
3- Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020 Apr 13. pii: 137647. doi: 10.1172/JCI137647.
4- Wang B, Kovalchuk A, Dongping L, et al. In Search of Preventative Strategies: Novel AntiInflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues. Preprints 2020, 2020040315 (doi: 10.20944/preprints202004.0315.v1)
5- Iffland K., Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017;2:139–154. doi: 10.1089/can.2016.0034.
6- Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015 Oct;172(20):4790-805. doi: 10.1111/bph.13250. Epub 2015 Oct 13. PMID: 26218440; PMCID: PMC4621983.
7- Pauli CS, Conroy M, Vanden Heuvel BD, Park SH. Cannabidiol Drugs Clinical Trial Outcomes and Adverse Effects. Front Pharmacol. 2020 Feb 25;11:63. doi: 10.3389/fphar.2020.00063. PMID: 32161538; PMCID: PMC7053164.
8- Ribeiro A, Almeida VI, Costola-de-Souza C, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Gimenes-Junior JA, Akamine AT, Crippa JA, Tavares-de-Lima W, Palermo-Neto J. Cannabidiol improves lung function and inflammation in mice submitted to LPS-induced acute lung injury. Immunopharmacol Immunotoxicol. 2015 Feb;37(1):35-41. doi: 10.3109/08923973.2014.976794. Epub 2014 Oct 30.
9- Ribeiro A, Ferraz-de-Paula V, Pinheiro ML, Vitoretti LB, Mariano-Souza DP, Quinteiro-Filho WM, Akamine AT, Almeida VI, Quevedo J, Dal-Pizzol F, Hallak JE, Zuardi AW, Crippa JA, Palermo-Neto J. Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: role for the adenosine A(2A) receptor . Eur J Pharmacol. 2012 Mar 5;678(1-3):78-85. doi: 10.1016/j.ejphar.2011.12.043. Epub 2012 Jan 12.
10- O’Sullivan SE, Kendall D. Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease. Immunobiology 2010; 215: 611–616.
11- Huang S, Goplen NP, Zhu B, Cheon IS, Son Y, Wang Z, Li C, Dai Q, Jiang L, Xiang M, Carmona EM, Vassallo R, Limper AH, Sun J. Macrophage PPAR-γ suppresses long-term lung fibrotic sequelae following acute influenza infection. PLoS One. 2019 Oct 4;14(10):e0223430. doi: 10.1371/journal.pone.0223430. PMID: 31584978; PMCID: PMC6777801.
12- Al-Qahtani AA, Lyroni K, Aznaourova M, Tseliou M, Al-Anazi MR, Al-Ahdal MN, Alkahtani S, Sourvinos G, Tsatsanis C. Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ. Oncotarget. 2017 Feb 7;8(6):9053-9066. doi: 10.18632/oncotarget.14754. PMID: 28118607; PMCID: PMC5354714.
13- Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R. PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol. 2010;23:343–352. doi: 10.1089/vim.2010.0016.
14- Omeragic A, Hoque MT, Choi UY, Bendayan R. Peroxisome proliferator-activated receptor-gamma: potential molecular therapeutic target for HIV-1-associated brain inflammation. J Neuroinflammation. 2017 Sep 8;14(1):183. doi: 10.1186/s12974-017-0957-8. PMID: 28886715; PMCID: PMC5591559.
15- Arnold R, Neumann M, König W. Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x. PMID: 17425601; PMCID: PMC2265928.
16- Lowe HI, Toyang NJ, McLaughlin W. Potential of Cannabidiol for the Treatment of Viral Hepatitis. Pharmacognosy Res. 2017 Jan-Mar;9(1):116-118. doi: 10.4103/0974-8490.199780. PMID:
28250664; PMCID: PMC5330095.
17- Ng FH, Li SK, Lee YC, Ma JKF. Temporal changes in computed tomography of COVID-19 pneumonia with perilobular fibrosis. Hong Kong Med J. 2020 Apr 29. doi: 10.12809/hkmj208490.
18- Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM et al  (2008). PPAR‐γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin‐induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L891–L901.
19- Vuolo, F., Abreu, S. C., Michels, M et al. Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. European Journal of Pharmacology 2018. doi:10.1016/j.ejphar.2018.11.029
20- Larsen C, Shahinas J. Dosage, Efficacy and Safety of Cannabidiol Administration in Adults: A Systematic Review of Human Trials. J Clin Med Res. 2020 Mar;12(3):129-141. doi: 10.14740/jocmr4090. Epub 2020 Mar 2.